Latest Stock Buy or Sell? Make More Informed Decisions!

(A top pick October 18/17, down 5%) This has been underwhelming. Were early in getting involved in the name. Have struggled with the debt load they inherited. But stock is back in gear. They got approval on their Line 3 replacement. They have cleaned up their complex corporate structure. Have divested of some core assets. Has a 6% yield and guidance to grow their dividend 10% over the next year or so.

(A top pick October 18/17, down 1%) This one is still in the starting gate. This is the heaviest weighted bank in their portfolio. Scotiabank is the poster child for emerging market exposure with operations in Mexico, Latin America, and South America. They are getting bigger in those geographies. And have double downed on wealth management with the acquisition of MD Management. Sentiment changing in emerging markets should put it back on track.

(A top pick October 18/17, up 22%) This has been a winner and continue to own it. This is a very consistent growth story in the Canadian technology space. Came out with numbers that were slightly below on top line, operating line and earnings. But miss was small. Amount of organic growth has slowed, but historically organic growth is slow. He would continue to hold this stock. They are a prolific cash machine and very profitable. They are buying back stock and making small acquisitions. Does provide double digit earnings growth so provides good value. He is very comfortable with this name.

Do not have a final investment decision on the LNG plant project yet. Should have a decision on this project sometime this year. Most are thinking the big LNG plant will get built. Most western Canadian natural gas stocks are very cheap. Western Canada is awash in natural gas and North America does not need it. If LNG gets exported globally, will see an enormous boom. Arc is a low cost, high quality operator in this area and may be some merit to own a small position in hope the plant gets built. There is an element of speculation.

Earnings were not very good. He would likely not have the nerve to short this stock. Shorting a stock has unlimited downside. Has avoided this sector altogether. Marijuana until proven otherwise is an agricultural commodity. This is not a branded product and does not have the margins of branded products. Is more a show me stock.

The stock is not going down because of trade tensions. It operates entirely in Canada. They are good at sourcing product to maintain their margins. The stock is declining because trend is rotating away from growth stocks to more valued stocks. The growth is decelerating. Would be very interested in this at a lower price. He is not sure if the current pull back is over yet.

This will give you passive exposure to the 60 largest companies in Canada. So the ETF will mirror whatever that index does. It pays a dividend of about 3%. Absent active management , it is a good way to get passive exposure to Canadian large caps.

This will give you passive exposure to the 60 largest companies in Canada. So the ETF will mirror whatever that index does. It pays a dividend of about 3%. Absent active management , it is a good way to get passive exposure to Canadian large caps.

He would be wary of this stock. They have had a pattern of disappointing earnings, and not likely out of the woods yet. There is political unrest in Nicaragua where they operate.

Is a midsize, rapidly growing Canadian based but Columbia operating energy producer. Has some of the highest operating profits in the oil patch. There are 2 pipelines that allow them to get their product to tide water. It has grown quickly. It has quadrupled cash flow and gives a 26% return on shareholders’ equity. The catalyst has opened up a strategic review process and effectively has put the company up for sale so could see this company sold to a larger player. (Analysts’ price target is $ 32.55)

This is a recent addition to their portfolio. Loblaw runs some dominant banners in both grocery retailing and pharmacy. Have accelerated their organic growth with the purchase of Shoppers Drugmart. They have gained market share and shown margin improvement. We like what they are doing operationally and financially. Stock is trading at 14X earnings. The value of growth and consistency in this name is exceptional. (Analysts’ price target is $76.92)

Brookfield is one of the world’s foremost manager of alternative long duration assets. They manage around $200B in assets. They have tremendous financial strength and a variety of funding sources. It is a complex corporate structure. They attract capital from other institutional investors. They have deep expertise. (Analysts’ price target is $62.32)